Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

Sunny3999 Feb. 18 at 5:11 PM

$PMN NEXT STOP $50 $JNJ $LLY $PFE $REGN

0 · Reply

DragonAlgo Feb. 18 at 4:52 PM

🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-02-20 | Strike: $245.00 | Type: CALL Option Plan (premium): Entry: $1.12 Stop: $0.81 TP1: $1.46 TP2: $1.90 TP3: $2.69 Risk preset by model constraints. 🔗 https://dragonalgo.com

0 · Reply

BigMoneyClip Feb. 18 at 3:39 PM

$JNJ looking to test a 5-7% break out this week.

0 · Reply

LiveSquawk Feb. 18 at 3:16 PM

$JNJ | Johnson & Johnson Expands U.S. Footprint With More Than $1 Billion Investment In Next Generation Cell Therapy Manufacturing Facility In Pennsylvania https://www.jnj.com/media-center/press-releases/draft

0 · Reply

BLD33 Feb. 18 at 2:29 PM

$SNSE how many weakness moments were the Opportunity moments to buy The same with $ACIU I’m buying more $JNJ partnership will last and stock will make 100-300-500% gains

0 · Reply

SenefAS Feb. 18 at 8:55 AM

Genmab ah this level it’s undervalued - The results are good not the best but good - Next news on pipe-line Will be a electrochoc Jefferies put a target at 2650DK $GMAB $JNJ $ABBV #biotech $XBI

0 · Reply

Suite510 Feb. 18 at 2:35 AM

$JNJ $KVUE $SPX $SPY Current average Ovarian Talc verdict is 13 Million dollars lol 😂 x 67,000

1 · Reply

Suite510 Feb. 18 at 2:05 AM

$JNJ $KVUE $SPX $SPY Like i stated last year a bunch of clowns 🤡 running JNJ talc strategy In March 2025, the company vowed to “defeat these meritless talc claims.” J&J insisted that the lawsuits, which argue that the company’s talc products cause ovarian cancer, were based on “junk science. Almost a year later, J&J is still looking for its first trial win since the settlement failed. 🤣🙈

0 · Reply

The__short_squeezer Feb. 17 at 9:10 PM

$LLY $JPM $XOM $V $JNJ

0 · Reply

DragonAlgo Feb. 17 at 8:54 PM

🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-02-20 | Strike: $245.00 | Type: CALL Option Plan (premium): Entry: $1.35 Stop: $0.98 TP1: $1.76 TP2: $2.30 TP3: $3.25 System-defined risk profile. 🔗 https://dragonalgo.com

0 · Reply

Johnson & Johnson to Invest More Than $1 Billion in Pennsylvania Cell Therapy Factory

Feb 18, 2026, 10:17 AM EST - 2 hours ago

J&J to invest $1 billion in new Pennsylvania plant amid US manufacturing push

Feb 18, 2026, 10:15 AM EST - 2 hours ago

Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania

Feb 18, 2026, 7:30 AM EST - 5 hours ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

Feb 17, 2026, 8:00 AM EST - 1 day ago

FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

Feb 17, 2026, 6:23 AM EST - 1 day ago

Dividend Income: Lanny's December 2025 Summary

ADM AFL EMR GWW IBM LYB MCD

Feb 13, 2026, 4:19 PM EST - 4 days ago

Johnson & Johnson found liable for cancer in latest talc trial, ordered to pay $250K

Feb 13, 2026, 4:18 PM EST - 4 days ago

Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial

Feb 13, 2026, 2:43 PM EST - 4 days ago

Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial

Feb 13, 2026, 7:00 AM EST - 5 days ago

After A 55% Surge, Is JNJ Stock Still A Buy?

Feb 11, 2026, 2:23 PM EST - 6 days ago

NIH Stops Johnson & Johnson's Blood Thinner Drug Arm In Stroke Trial After Safety Review

Feb 9, 2026, 4:16 PM EST - 8 days ago

Johnson & Johnson to Participate in the Barclays 28th Annual Global Healthcare Conference

Feb 6, 2026, 7:00 PM EST - 11 days ago

Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium

Feb 5, 2026, 1:00 PM EST - 12 days ago

The Big 3: JNJ, XOM, KO

XOM KO

Feb 4, 2026, 1:37 PM EST - 13 days ago

These hot S&P 500 stocks show where investors are heading as they run away from tech

FDX NOC NSC RTX WMT XOM

Feb 3, 2026, 8:47 AM EST - 15 days ago

What's Behind The 50% Surge In JNJ Stock?

Feb 3, 2026, 3:00 AM EST - 15 days ago

Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens for Astigmatic Patients with Presbyopia in United Kingdom and Ireland

Feb 2, 2026, 4:34 PM EST - 15 days ago

Johnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference

Feb 1, 2026, 10:35 AM EST - 17 days ago

Ariel Focus Fund Q4 2025 Portfolio Review

ADT AMG B FISV MOS ORCL

Jan 30, 2026, 2:43 PM EST - 18 days ago

Johnson & Johnson: Fraud Claim Dismissal Today Is Not A Sign Talc Litigation Is Over

Jan 30, 2026, 7:19 AM EST - 19 days ago

Johnson & Johnson receives CHMP positive opinion for AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with BRCA1/2 mutations

Jan 29, 2026, 6:32 PM EST - 19 days ago

US judge tosses lawsuit accusing J&J of fraud over talc bankruptcy strategy

Jan 29, 2026, 12:42 PM EST - 19 days ago

This Winning Fund Pro Likes J&J, Lowe's, and Utility Stocks

LOW

Jan 28, 2026, 9:38 AM EST - 21 days ago

Johnson & Johnson: Strong Momentum Heading Into 2026

Jan 27, 2026, 3:49 PM EST - 21 days ago

DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible

Jan 27, 2026, 8:00 AM EST - 22 days ago

Johnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile

Jan 25, 2026, 10:11 PM EST - 23 days ago

Best Dividend Kings: January 2026

ABBV ABM ABT ADM ADP AWR BDX

Jan 22, 2026, 12:15 AM EST - 27 days ago

Johnson & Johnson is doing 'great things for patients,' CFO says

Jan 21, 2026, 11:20 PM EST - 27 days ago

Plaintiffs' Evidence Will Be Heard in Cases Alleging J&J's Talc Products Caused Women's Ovarian Cancer, Announced Levin Papantonio Attorney Chris Tisi

Jan 21, 2026, 6:45 PM EST - 27 days ago

Johnson & Johnson Says Product Launches, Regulatory Approvals Drive Growth

Jan 21, 2026, 1:56 PM EST - 27 days ago

Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript

Jan 21, 2026, 12:15 PM EST - 4 weeks ago

Nasdaq Edges Lower; Johnson & Johnson Earnings Top Estimates

Jan 21, 2026, 10:00 AM EST - 4 weeks ago

OKLO Upgrade Rally, ULTA Adds Bullish Momentum, JNJ Earnings

OKLO ULTA

Jan 21, 2026, 7:26 AM EST - 4 weeks ago

J&J expects to hit $100 billion in revenue next year after new strategy pays off

Jan 21, 2026, 6:23 AM EST - 4 weeks ago

Johnson & Johnson forecasts 2026 profit above Wall Street estimates

Jan 21, 2026, 6:20 AM EST - 4 weeks ago

J&J's Sales and Profit Rise on Strong Cancer and Autoimmune Drug Sales

Jan 21, 2026, 6:20 AM EST - 4 weeks ago

Johnson & Johnson reports Q4 and Full-Year 2025 results

Jan 21, 2026, 1:07 AM EST - 4 weeks ago

Johnson & Johnson Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Jan 20, 2026, 8:37 AM EST - 4 weeks ago

How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q4 Earnings

Jan 19, 2026, 8:00 AM EST - 4 weeks ago

Is Johnson & Johnson A Dividend Stock, Or Something Else?

Jan 19, 2026, 5:08 AM EST - 4 weeks ago

Johnson & Johnson: Tempering Expectations After A Massive 2025 (Downgrade)

$TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide$

Jan 14, 2026, 4:30 PM EST - 4 weeks ago

TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide

Jan 13, 2026, 8:00 AM EST - 5 weeks ago

Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting

Jan 13, 2026, 2:40 AM EST - 5 weeks ago

Mar Vista U.S. Quality Q4 2025 Top Contributors And Detractors

DHR GOOG LIN MSFT ORCL

Jan 12, 2026, 6:32 PM EST - 5 weeks ago

Johnson & Johnson's $1 billion loss from robotics takeover reduced by Delaware top court

Jan 12, 2026, 2:06 PM EST - 5 weeks ago

Johnson & Johnson (JNJ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 11, 2026, 7:40 AM EST - 5 weeks ago

The 2026 Dogs Of The Dow: 10 High-Yield Blue Chips

AMGN CVX HD KO MRK NKE PG

Jan 10, 2026, 10:00 AM EST - 5 weeks ago

RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer

Jan 10, 2026, 9:52 AM EST - 5 weeks ago

January Dogs Of The Dow: One Ideal 'Safer' Dividend Buy

AMGN CRM DIS HD HON KO MRK

Jan 9, 2026, 9:59 AM EST - 5 weeks ago

Cramer's Mad Dash: Johnson & Johnson

Sunny3999 Feb. 18 at 5:11 PM

$PMN NEXT STOP $50 $JNJ $LLY $PFE $REGN

0 · Reply

DragonAlgo Feb. 18 at 4:52 PM

0 · Reply

BigMoneyClip Feb. 18 at 3:39 PM

$JNJ looking to test a 5-7% break out this week.

0 · Reply

LiveSquawk Feb. 18 at 3:16 PM

0 · Reply

BLD33 Feb. 18 at 2:29 PM

$SNSE how many weakness moments were the Opportunity moments to buy The same with $ACIU I’m buying more $JNJ partnership will last and stock will make 100-300-500% gains

0 · Reply

SenefAS Feb. 18 at 8:55 AM

Genmab ah this level it’s undervalued - The results are good not the best but good - Next news on pipe-line Will be a electrochoc Jefferies put a target at 2650DK $GMAB $JNJ $ABBV #biotech $XBI

0 · Reply

Suite510 Feb. 18 at 2:35 AM

$JNJ $KVUE $SPX $SPY Current average Ovarian Talc verdict is 13 Million dollars lol 😂 x 67,000

1 · Reply

Suite510 Feb. 18 at 2:05 AM

0 · Reply

The__short_squeezer Feb. 17 at 9:10 PM

$LLY $JPM $XOM $V $JNJ

0 · Reply

DragonAlgo Feb. 17 at 8:54 PM

0 · Reply

_ReversalTrackers Feb. 17 at 6:59 PM

$QNCX $HSAI $JNJ $LULU :

0 · Reply

___ReversalsTrackerz Feb. 17 at 5:21 PM

$JNJ $ZETA $TER $BURU (

0 · Reply

SpudZone Feb. 17 at 3:30 PM

Names like $BMY $VZ $JNJ are having unbelievable starts to 2026 as tech continued to slide... Traders are piling into defensive Dividend names. Charts look incredible... Keep an eye on calls when these names dip, MM continues to move them higher the last 2-3 weeks. $SPY $QQQ

0 · Reply

VoidGorilla Feb. 17 at 3:15 PM

$JNJ $DX $ABNB $LRCX >>>€>

0 · Reply

Suite510 Feb. 17 at 2:44 PM

$JNJ $KVUE $SPX $SPY Rocky always wins 🏆😂🙈 It is how a pattern of jury decisions in ovarian cancer and mesothelioma cases could influence Johnson & Johnson’s aggregate liability and any eventual settlement structure. Recent trials include a US$40M award in Los Angeles County and more than US$2B in trial losses in late 2025 on mesothelioma claims, which keeps the potential range of future cash outflows in focus.

0 · Reply

outlawinvestor1 Feb. 17 at 2:40 PM

$ATAI $JNJ $HELP $CMPS comp360 data today is a win for psychedelics space, but commercial path is limited for this drug. bpl003 and hlp003/hlp004 have a better chance.

0 · Reply

Suite510 Feb. 17 at 2:22 PM

$JNJ $KVUE jerk n jerk going to pay big time 😂 This is the first decision in a new round of talc trials after years of litigation delays. currently faces more than 70,000 talc-related lawsuits. Recent findings from the International Agency for Research on Cancer and NIH have elevated the probable cancer risk of genital talc use.

0 · Reply

Manuelos Feb. 17 at 2:10 PM

$JNJ 242, I’m flat, no trade until 246.35 breaks or fails

0 · Reply

NetworkNewsWire Feb. 17 at 2:05 PM

Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A $OTLC $ARWR $MGTX $SUPN $JNJ https://ibn.fm/8zb4f

1 · Reply

Phase3 Feb. 17 at 1:47 PM

$JNJ Only $250K... sentiment is changing...

0 · Reply

Suite510 Feb. 17 at 12:30 PM

$JNJ $KVUE $LLYX.X News broke late Friday so jerk n jerk survives another day 😂 for now

1 · Reply

3DBuilds Feb. 17 at 12:05 PM

$NTLA $CRBU $EDIT $PRME $JNJ Jennifer 💯 💰 🌎

0 · Reply

Market Cap	586.69B
Revenue (ttm)	94.19B
Net Income (ttm)	26.80B
EPS (ttm)	N/A
PE Ratio	22.64
Forward PE	21.20
Profit Margin	28.46%
Debt to Equity Ratio	0.50

Volume	12,703,009
Avg Vol	8,927,198
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	77%
Beta	0.35
Analysts	Strong Sell
Price Target	$233.28